Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
D015250:Aclarubicin; D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced; D000880:Anthraquinones / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000008:administration & dosage; D016227:Benzoquinones; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone; D009279:Naphthacenes / Q000008:administration & dosage
D000880:Anthraquinones; D001388:Aziridines; D016227:Benzoquinones; D009279:Naphthacenes; D015250:Aclarubicin; D008942:Mitoxantrone; C029108:diaziquone